NATCO launches Epilepsy Tablets in India

NATCO’s BRECITA tablets will be available in two strengths of 50mg and 100mg at MRP prices of Rs 25/- and Rs 35/- per tablet respectively.

106
NATCO launches Epilepsy Tablets in India

Last Updated on March 2, 2021 by The Health Master

Natco Pharma announced the launch of Brivaracetam tablets under brand BRECITA in India.

Brivaracetam is indicated for the treatment of epilepsy. Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under the brand name Briviact.

NATCO’s BRECITA tablets will be available in two strengths of 50mg and 100mg at MRP prices of Rs 25/- and Rs 35/- per tablet respectively.

Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.


Also read:

ICPA launches antibiotic for Dental treatment

Zydus Cadila gets USFDA nod for Anti Depressant drug

Granules gets USFDA nod for Acetaminophen, Aspirin and Caffeine tablets

Strides gets USFDA Yes for Ibuprofen OTC Oral Suspension

Sun Pharma to launch entire range of Epilepsy treatment drug in India

Dr Reddy’s launch Lansoprazole DR orally disintegrating tablets


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram..

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading